DDInter469 DDInter1840
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Mycophenolic acid {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Loratadine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Toremifene {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Crizotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Dalfopristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib (Compound) binds SRC (Gene) and Crizotinib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)